Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

Yael L. Maxwell

October 26, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

March 25, 2012

Optimizing the Duration of DAPT following PCI

CME

Optimizing the Duration of DAPT following PCI

PLX Pharma - Aspirin for the Interventionalist: More Than Meets the Eye

CME

Aspirin for the Interventionalist: More Than Meets the Eye

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

CME

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.